1. Home
  2. CTSO vs AIRE Comparison

CTSO vs AIRE Comparison

Compare CTSO & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • AIRE
  • Stock Information
  • Founded
  • CTSO 1997
  • AIRE 2021
  • Country
  • CTSO United States
  • AIRE United States
  • Employees
  • CTSO N/A
  • AIRE 14
  • Industry
  • CTSO Medical/Dental Instruments
  • AIRE
  • Sector
  • CTSO Health Care
  • AIRE
  • Exchange
  • CTSO Nasdaq
  • AIRE Nasdaq
  • Market Cap
  • CTSO 48.2M
  • AIRE 53.2M
  • IPO Year
  • CTSO N/A
  • AIRE N/A
  • Fundamental
  • Price
  • CTSO $0.86
  • AIRE $1.14
  • Analyst Decision
  • CTSO Strong Buy
  • AIRE Strong Buy
  • Analyst Count
  • CTSO 3
  • AIRE 1
  • Target Price
  • CTSO $4.67
  • AIRE $3.00
  • AVG Volume (30 Days)
  • CTSO 135.6K
  • AIRE 64.9K
  • Earning Date
  • CTSO 11-07-2024
  • AIRE 12-24-2024
  • Dividend Yield
  • CTSO N/A
  • AIRE N/A
  • EPS Growth
  • CTSO N/A
  • AIRE N/A
  • EPS
  • CTSO N/A
  • AIRE N/A
  • Revenue
  • CTSO $37,739,531.00
  • AIRE $379,241.00
  • Revenue This Year
  • CTSO $8.08
  • AIRE $571.65
  • Revenue Next Year
  • CTSO $12.80
  • AIRE $168.35
  • P/E Ratio
  • CTSO N/A
  • AIRE N/A
  • Revenue Growth
  • CTSO 1.80
  • AIRE 18.11
  • 52 Week Low
  • CTSO $0.70
  • AIRE $0.53
  • 52 Week High
  • CTSO $1.97
  • AIRE $3.10
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 42.77
  • AIRE 55.31
  • Support Level
  • CTSO $0.80
  • AIRE $1.14
  • Resistance Level
  • CTSO $1.09
  • AIRE $1.23
  • Average True Range (ATR)
  • CTSO 0.08
  • AIRE 0.07
  • MACD
  • CTSO -0.00
  • AIRE 0.00
  • Stochastic Oscillator
  • CTSO 13.19
  • AIRE 63.16

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.

Share on Social Networks: